Sareum Holdings PLC (GB:SAR)
LSE:SAR
Top Page
Sareum Holdings
(LSE:SAR)
Select Model
Select Model
Rating:44Neutral
Price Target:
16.00 p
▲(6.67% Upside)
Action:ReiteratedDate:03/13/26
The score is driven mainly by weak financial performance typical of an early-stage, pre-revenue biotech (ongoing losses and cash burn), only partly offset by a debt-free balance sheet and slightly improved cash outflow. Technical indicators also point to a weak trend with depressed momentum, while valuation is constrained by negative earnings and no dividend support.
Positive Factors
Debt-free balance sheet
No reported debt removes fixed interest obligations and lowers insolvency risk, giving Sareum flexibility to structure financing, extend runway or prioritise R&D spend. Over the next 2–6 months this durable financial buffer supports partner negotiations and reduces refinancing pressure.
Negative Factors
Pre-revenue and persistent losses
Sareum remains pre-revenue with recurring operating and net losses, meaning the business cannot self-fund operations. Over 2–6 months this structural lack of commercial income forces reliance on external financing, increasing dilution and execution risk for development programmes.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
No reported debt removes fixed interest obligations and lowers insolvency risk, giving Sareum flexibility to structure financing, extend runway or prioritise R&D spend. Over the next 2–6 months this durable financial buffer supports partner negotiations and reduces refinancing pressure.
Read all positive factors
Sareum Holdings (SAR) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£22.09M
Dividend YieldN/A
Average Volume (3M)619.72K
Price to Earnings (P/E)―
Beta (1Y)-0.40
Revenue GrowthN/A
EPS Growth23.76%
CountryUK
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding138,065,170
10 Day Avg. Volume1,134,615
30 Day Avg. Volume619,716
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)8.68
Price to Sales (P/S)0.00
P/FCF Ratio-7.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)£43.15M
Sareum Holdings Business Overview & Revenue Model
Company Description
Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library...
How the Company Makes Money
Sareum’s primary way of generating income is through the monetisation of its drug discovery and development assets rather than product sales. This typically includes (1) partnering/licensing arrangements where third parties obtain rights to Sareum...
Sareum Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -1.00K | -1.00K | -2.00K | -1.09K |
| EBITDA | -5.40M | -3.38M | -4.54M | -4.01M | -2.57M | -1.70M |
| Net Income | -4.93M | -4.44M | -3.42M | -3.19M | -2.17M | -1.50M |
Balance Sheet | ||||||
| Total Assets | 3.23M | 4.23M | 2.77M | 2.02M | 4.79M | 3.08M |
| Cash, Cash Equivalents and Short-Term Investments | 2.49M | 3.55M | 1.46M | 994.00K | 4.26M | 2.69M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.04M | 1.95M | 653.00K | 867.00K | 455.00K | 284.15K |
| Stockholders Equity | 1.19M | 2.28M | 2.11M | 1.15M | 4.33M | 2.80M |
Cash Flow | ||||||
| Free Cash Flow | -3.25M | -2.55M | -3.92M | -3.27M | -2.13M | -1.57M |
| Operating Cash Flow | -3.25M | -2.55M | -3.92M | -3.27M | -2.13M | -1.57M |
| Investing Cash Flow | 12.00K | 89.00K | 9.00K | -41.00K | -2.00K | -37.86K |
| Financing Cash Flow | 1.58M | 4.55M | 4.38M | 0.00 | 3.71M | 2.49M |
Sareum Holdings Technical Analysis
Positive
15.00
Price Trends
16.58
Negative
15.84
Positive
17.66
Negative
Market Momentum
-0.06
Negative
52.88
Neutral
72.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SAR, the sentiment is Positive. The current price of 15 is below the 20-day moving average (MA) of 15.35, below the 50-day MA of 16.58, and below the 200-day MA of 17.66, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 52.88 is Neutral, neither overbought nor oversold. The STOCH value of 72.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:SAR.
Sareum Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | £25.86M | -1.64 | -197.54% | ― | 3.31% | 21.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £29.61M | -1.92 | -53.86% | ― | ― | ― | |
46 Neutral | £23.13M | -3.00 | 3817.30% | ― | ― | ― | |
44 Neutral | £22.09M | -3.13 | -202.14% | ― | ― | 23.76% | |
44 Neutral | £15.94M | -9.67 | -210.32% | ― | -11.43% | 23.40% | |
40 Underperform | £16.18M | -6.19 | -213.66% | ― | 39.88% | 81.33% |
* Healthcare Sector Average
GB:SAR
Sareum Holdings
16.00
2.50
18.52%
GB:IMM
ImmuPharma
4.60
1.55
50.82%
GB:FAB
Fusion Antibodies Plc
12.75
6.60
107.32%
GB:POLB
Poolbeg Pharma Ltd.
4.20
1.45
52.73%
GB:AREC
Arecor Therapeutics PLC
68.50
25.00
57.47%
GB:APTA
Aptamer Group Plc
0.60
0.34
130.77%
Sareum Holdings Corporate Events
Business Operations and StrategyFinancial Disclosures
Sareum Restarts Key Toxicology Study as TYK2 Pipeline and Partnering Drive Half-Year Progress
Positive
Mar 12, 2026
Sareum Holdings reported half-year results to 31 December 2025, underscoring progress on its pipeline of kinase inhibitors for autoimmune disease, cancer and neuroinflammation, while ending the period with £2.5 million in cash and a reduced p...
Business Operations and StrategyFinancial Disclosures
Sareum to Release Interim Results and Host Live Investor Presentation
Neutral
Mar 3, 2026
Sareum Holdings said it will publish its unaudited interim financial results for the six months to 31 December 2025 on 12 March 2026. The update will give investors a mid-year view on the progress and financial health of the company as it advances...
Business Operations and StrategyProduct-Related Announcements
Sareum Restarts Phase 2-Enabling Toxicology Programme for Lead Autoimmune Drug SDC-1801
Positive
Feb 17, 2026
Sareum Holdings has restarted its Phase 2-enabling toxicology programme for SDC-1801, a selective TYK2/JAK1 inhibitor in development for autoimmune diseases with an initial focus on psoriasis, after appointing a leading global contract research or...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.